* Disclaimer:  Our products and technologies are currently not available for clinical use. FDA or other regulatory agencies have not evaluated the statements on this website regarding our products and technologies. 

Theragnostic Tech Receives NIH Small Business Innovation Research (SBIR) Phase 2 Award

July 15, 2015

Theragnostic Technologies has received Small Business Innovation Research  (SBIR) Phase 2 grant from the National Institute of Diabestes and Digestive and Kidney Diseases. This SBIR phase 2 project focuses on preclinical investigational new drug (IND) enabling studies of a novel high performance carbon nanostructure-ased magnetic resonance imaging (MRI) contrast agent (CA) to be used to diagnose and monitor patients with renal failure. 

 

 

Please reload

Recent Posts
Please reload